A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT02450331
- Phase
- PHASE3
- Status
- Terminated
Conditions
- Carcinoma, Transitional Cell
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Atezolizumab — DRUGAtezolizumab will be administered at a dose of 1200 milligrams (mg).
Study Details
This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants were randomized by a 1:1 ratio into atezolizumab group or control group.
Key Dates
- Start date
- Oct 5, 2015
- Status verified
- May 2023
- Primary completion
- Nov 30, 2019
- Completion
- Jun 14, 2022
Study Design
- Enrollment
- 809 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: AtezolizumabParticipants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
- No Intervention: ObservationParticipants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).
Primary Outcome Measure
Disease-Free Survival (DFS), as Assessed by Investigator [ Time Frame: Randomization up to first occurrence of DFS event (up to approximately 50 months) ]
Locations (41)
Find similar trials in Scottsdale, AZ
Related Studies
- uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With JelmytoRecruiting · UroGen Pharma Ltd. · Santa Monica, California
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractPHASE3 · Recruiting · Eli Lilly and Company · Huntsville, Alabama